John Stanton - Nanobac Pharmaceuticals Chairman of the Board, CEO, CFO
| NNBP Stock | USD 0.0001 0.00 0.00% |
Chairman
Mr. Stanton has served as the Chief Executive Officer July 23, 2004 to present and from March 2001 through January 2004. From March, 2001 through the present, Mr. Stanton has served as Chairman of the Board of Directors and Chief Financial Officer. From 1987 through the present, Mr. Stanton served as the President and CEO of a private company headquartered in Tampa Florida engaged in the business of manufacturing residential concrete construction products. Mr. Stanton has served as Chairman of the Board of Directors of publiclytraded EarthFirst Technologies, Incorporated from May 15, 2000 through the present. Mr. Stanton also serves on the Board of Directors of publicly traded Medical Technology Systems, Inc., and several other public companies. Mr. Stanton worked as an auditor with the international professional services firm that is now known as Ernst Young, LLP from 1973 through 1981. Mr. Stanton, a Vietnam veteran of the United States Army, graduated from the University of South Florida with a Bachelors Degree in Marketing and Accounting in 1972, and with an MBA in 1973 since 2004.
| Age | 62 |
| Tenure | 21 years |
| Professional Marks | CPA |
| Phone | 813-865-1125 |
John Stanton Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Stanton against Nanobac Pharmaceuticals stock is an integral part of due diligence when investing in Nanobac Pharmaceuticals. John Stanton insider activity provides valuable insight into whether Nanobac Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Nanobac Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nanobac Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Stanton over a year ago Under Armour exotic insider transaction detected | ||
John Stanton over a year ago Under Armour exotic insider transaction detected |
Nanobac Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3684) % which means that it has lost $0.3684 on every $100 spent on assets. This is way below average. Nanobac Pharmaceuticals' management efficiency ratios could be used to measure how well Nanobac Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Eric Weisblum | Silo Pharma | 54 | |
Management Performance
| Return On Asset | -0.37 |
Nanobac Pharmaceuticals Leadership Team
Elected by the shareholders, the Nanobac Pharmaceuticals' board of directors comprises two types of representatives: Nanobac Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nanobac. The board's role is to monitor Nanobac Pharmaceuticals' management team and ensure that shareholders' interests are well served. Nanobac Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nanobac Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Benedict Maniscalco, Medical Research | ||
| John Stanton, Chairman of the Board, CEO, CFO | ||
| Olavi Kajander, Chief OY | ||
| Neva Ciftcioglu, Director CoFounder |
Nanobac Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nanobac Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.37 | ||||
| Operating Margin | (151.42) % | ||||
| Current Valuation | 124.75 K | ||||
| Price To Earning | (0.02) X | ||||
| Price To Sales | 7.08 X | ||||
| Revenue | 17.62 K | ||||
| Gross Profit | 3.1 K | ||||
| EBITDA | (3.97 M) | ||||
| Net Income | (6.58 M) | ||||
| Cash And Equivalents | 3.93 K |
Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.